Optimizing Care for Diverse Patient Populations with Migraine: An Exploration of Migraine Management with a Focus on CGRP Receptor Antagonists


Cynthia E. Armand, MD
Associate Professor of Neurology, Albert Einstein College of Medicine
Fellowship Director, Montefiore Headache Center
Clinical Director, Montefiore Headache Center
Bronx, NY
Susan L. Hutchinson, MD
Director and Founder
Orange County Migraine & Headache Center
Irvine, CA 
Peter J. Goadsby, MBBS, MD, PhD
Professor of Neurology 
Director, Clinical Research Facility  
King's College London 
Professor (Emeritus) of Neurology  
University of California, Los Angeles 
Los Angeles, CA 
Peter J. Goadsby, MBBS, MD, PhD



Statement of Need

Migraine is the most common neurological disorder, and the second most common cause of disability in the world. Despite the enormous cost it exacts on patients, the healthcare system, and the greater economy, migraine remains largely undertreated or un-treated. Racial disparities in treatment and outcomes also persist. Even though migraine prevalence is very similar among White, Black, and Latino/Hispanic groups, Black and Latino/Hispanic patients are less likely to even receive a migraine diagnosis than their White peers. Even after diagnosis, patients face unmet treatment needs. Common medications used to treat migraine attacks are poorly tolerated, contraindicated, or simply ineffective in some patients. Newer disease-process-specific therapies may offer hope to patients for whom traditional therapies are ineffective, poorly tolerated, or contraindicated.

During this educational presentation, migraine experts will share real-world examples of screening, diagnosis, and implementation of appropriate pharmacotherapy factoring in social determinants of health and patient access to care.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

  • Develop strategies to address unmet needs for diverse and underserved patient populations with migraine
  • Utilize validated screening tools and diagnostic aids, such as the ICHD-3 criteria to diagnose acute migraine
  • Incorporate the latest efficacy data for the role of CGRP receptor antagonists into decision-making for the acute treatment and prevention of episodic migraine

Financial Support

Supported through an independent educational grant from Pfizer Inc.

Target Audience

Primary care physicians, nurse practitioners (NPs), physician associates (PAs), RNs, neurologists, headache specialists, and pharmacists

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional (IPCE) 1.0

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education Credit for learning and change.

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this Enduring Material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 1.0

This activity is designated for 1.00 contact hours.

California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters LLC’s provider number is CEP15510.

Pharmacists (ACPE) 1.0

This application-based activity is approved for 1.00 contact hours ( 0.1 CEUs) of continuing pharmacy credit (JA0007185-0000-24-025-H01-P).

PAs (AAPA) 1.00

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until 01/23/2025. PAs should only claim credit commensurate with the extent of their participation.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

Dr. Goadsby reports the following financial relationships:

Advisory Board: AEON Biopharma, Inc.; Abbvie Inc.; Amgen Inc.; CoolTech LLC; Dr. Reddy’s Laboratories Ltd; Eli Lilly and Company; Epalex Corp.; LinPharma; Lundbeck; Novartis; Pfizer Inc.; Sanofi; Satsuma Pharmaceuticals, Inc.; ShiraTronics; Teva Pharmaceuticals Industries Ltd; and Tremeau Pharmaceuticals, Inc.

Grants: Celgene Corporation and Kallyope

Dr. Armand reports the following financial relationships:

Advisory Board: Linpharma and Tonix Pharmaceuticals

Consultant: Pfizer Inc.

Grants: Miles for Migraine (fellowship grant)

Dr. Hutchinson reports the following financial relationships:

Advisory Board and Consultant:
AbbVie Inc.; Astellas Pharma Inc.; Biohaven; Impel Pharmaceuticals Inc.; Lilly; Lundbeck; Pfizer Inc.; Teva Pharmaceuticals USA, Inc.; Theranica Bio-Electronics; and Upsher-Smith Laboratories, LLC

Speakers Bureau:
AbbVie Inc.; Astellas Pharma Inc.; Impel Pharmaceuticals Inc.; Lilly; and Lundbeck
The following individuals have no financial relationships to disclose: 

Rebecca Vargas-Jackson, MD  (Peer Reviewer)
Michael Franks, APRN, AGACNP-BC, FNP-BC (Peer reviewer)
Evan Luberger (Planning Committee)
John Jones, PharmD (Planning Committee)
Susan H. Yarbrough, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).


Optimizing Care for Diverse Patient Populations with Migraine: An Exploration of Migraine Management with a Focus on CGRP Receptor Antagonists
Event Date: 01/23/2024 at 5:00 am EST